Activation of pregnane X receptor (PXR), a nuclear receptor that controls xenobiotic and endobiotic metabolism, is known to induce liver enlargement, but the molecular signals and cell types responding to PXR-induced hepatomegaly remain unknown. In this study, the effect of PXR activation on liver enlargement and cell change was evaluated in several strains of genetically modified mice and animal models. Lineage labeling using AAV-Tbg-Cre-treated Rosa26 EYFP mice or Sox9-Cre 
Moreover, the liver modulates its size in response to physio-and pathological stimuli, for instance, hormonal fluctuations associated with pregnancy and lactation, acute-phase proteins involved in viral and bacterial infection, and enzymes that metabolize xenobiotics. (2) Furthermore, the liver has a tremendous capacity to regenerate after toxin-induced injury or surgical resection. However, the molecular mechanisms involved in regulation of liver size and regeneration are highly complicated and remain unclear.
Yes-associated protein (YAP) is a critical regulator of liver size that rapidly switches hepatic growth on or off. (3, 4) YAP hyperactivation can evoke proliferation and transdifferentiation of mature hepatocytes and part of the embryonic hepatic program. (5) Expression and activity of YAP are critical for the process of liver regeneration (LR), (6) but the YAP activation context and its impact on liver enlargement and regeneration remain largely unclear.
Many cell types are changed within the liver in response to alterations in liver size and LR. During LR, differentiated hepatocytes re-enter the cell cycle, proliferate, and replenish lost tissue. (7, 8) Bipotential liver progenitor cells (LPCs) were proposed as the main source of new hepatocytes and ductal cells under conditions in which normal hepatocyte proliferation was severely impaired. (9, 10) In addition to cytokeratin 19 (CK19) and epithelial cell adhesion molecule (EpCAM), SRY (sex determining region Y)-box 9 (SOX9) was proposed as a novel marker for LPCs. (5) Several studies have shown that LPCs only minimally contributed to restoring hepatocyte loss in most liver injury models. (11, 12) However, a specialized type of cells bearing characteristics of both LPCs and mature hepatocytes were identified as hybrid hepatocytes (HybHPs). These cells express both the LPC marker, SOX9, and the hepatocyte marker, hepatocyte nuclear factor 4α (HNF4α). They are considered a preexisting population of periportal hepatocytes located in the portal triads of healthy livers. HybHPs undergo extensive proliferation and replenish liver mass after chronic hepatocyte-depleting injury. (13) Thus, HybHPs may play critical roles in liver homeostasis and repair in response to injury.
Pregnane X receptor (PXR; NR1I2) is a ligand-activated transcription factor that belongs to the nuclear receptor superfamily. PXR is highly expressed in the liver and plays an integral role in control of xenobiotic and endobiotic metabolism to maintain homeostasis of numerous endobiotics, such as glucose, lipids, steroids, bile acids, bilirubin, retinoic acid, and bone minerals. (14, 15) Recent studies have explored the role of PXR in regulation of disease risk and severity, including development of cholestatic liver disease, (16) inflammatory bowel disease, (17) inflammatory liver disease, (18) cholesterol gallstone disease, (19) and nonalcoholic fatty liver disease. (20) As a potential important therapeutic target, fully understanding the biological and physiological properties and functions of PXR would be of great value. Most recently, a mouse-specific PXR agonist, pregnenolone-16α-carbonitrile (PCN), was found to induce significant liver enlargement. However, it is still unknown which cell types within the liver are responsible for the alterations in liver size, and the involved molecular signals remain poorly characterized. Risk of liver enlargement associated with PXR activators has not been extensively investigated and is important for rational clinical use of therapeutic drugs that are PXR agonists. The current study aimed to investigate the role of PXR in liver enlargement and determine the mechanisms accounting for its effect. Here, a physiological role for PXR was investigated, showing that it controls aRtiCle iNFoRMatioN:
liver size and changes cell fate by enlarging hepatocyte size, promoting hepatocyte proliferation, and inducing HybHP programming. Notably, PXR was found to interact with the YAP signaling pathway that is essential for PXR-induced liver enlargement. These findings indicated a function for PXR in controlling liver size and changing liver cell fate by the YAP signaling pathway, which helps us better understand the PXR physiological functions and provides a clinically relevant argument for using PXR as a potential therapeutic target to promote hepatic repair.
Materials and Methods

MoUSe StRaiNS
Eight-to 9-week-old male C57BL/6 mice, weighing 20-22 g, were provided by the Centre of Laboratory Animal Science of Guangdong (Guangzhou, China). Pxr-null mice (21) were obtained from Dr. Jeff L. Staudinger and Dr. Steven A. Kliewer. C57BL/6, Sox9-Cre ERT and Rosa26 EYFP reporter mice were obtained from The Jackson Laboratory (Bar Harbor, ME). All animal studies were approved by the Institutional Animal Care and Use Committee of Sun Yat-sen University (Guangzhou, China) or by the Institutional Animal Care and Use Committee of the National Institute on Alcohol Abuse and Alcoholism, the National Institutes of Health (Bethesda, MD).
StatiStiCal aNalySiS
Data are expressed as the means ± SD. One-way analysis of variance followed by unpaired Student t test or multiple t test was used for statistical analysis of data using GraphPad Prism software (version 5; GraphPad Software Inc., San Diego, CA). P values <0.05 were considered significant.
Other experimental information is provided in the Supporting Information.
Results
pXR aCtiVatioN iNDUCeD liVeR eNlaRgeMeNt
We first demonstrated PXR-induced liver enlargement using specific mouse or human PXR agonists in wild-type (WT) mice, Pxr-null mice, or PXRhumanized (hPXR) mice. After intraperitoneal injection of 100 mg/kg/d of pregnenolone-16α-carbonitrile (PCN) for 1-10 days, significant increases in liver-to-body-weight ratio were observed compared to the vehicle-treated group at the same time point (Supporting Fig. S1A,B) . Recovery of liver-to-bodyweight ratio to the normal ratio took 15 days after 5 days of PCN treatment (Supporting Fig. S1C,D) . WT and Pxr-null mice were then treated with vehicle or PCN for 5 days (Fig. 1A) . Absence of PXR expression abolished PCN-induced liver enlargement (Fig. 1B,C) . To examine change of hepatic cell size after PCN treatment, hepatocyte size was measured by hematoxylin and eosin (H&E) and β-catenin (CTNNB1) staining in WT and Pxr-null mice. An increase in hepatocyte size around the central vein (CV) was observed in PCN-treated WT mice, which was abolished in Pxr-null mice ( Fig. 1D-F) .
Human and mouse PXR have 95% homology in the DNA-binding domain, but only 73% homology in the ligand-binding domain. (22) To investigate whether liver overgrowth induced by PXR activation was species dependent, hPXR mice were administered 100 mg/kg of rifampicin (RIF), a human-specific PXR agonist, in the diet for 7 days (Fig. 2A) . As expected, a significant increase in liver-to-body-weight ratio was also observed in RIF-treated mice (Fig. 2B,C) . H&E and CTNNB1 staining revealed a significant increase in cell size in RIF-treated mice (Fig. 2D-F) . Interestingly, both in WT mice and hPXR mice, significant cell-size enlargement was mostly observed in the CV instead of portal vein (PV) area (Supporting Fig. S2A-F) . Because many therapeutic drugs were shown to affect PXR activity, (23) the influence of some of these drugs on liver size was investigated. Treatment with mifepristone, PCN, schisandrol B or dexamethasone for 5 days markedly induced liver enlargement (Supporting Fig. S2G-I ).
Increased liver size is known to be associated with inflammation and hepatotoxicity, (24) and thus several biochemical and inflammatory factors were measured to confirm whether PXR-induced liver enlargement was attributed to inflammation. No structural degenerative or necrotic changes were observed between the vehicle-treated group and the PCN-treated group, as revealed by H&E staining, inflammatory factors, myeloperoxidase (MPO) staining, and serum biochemical indexes (Supporting Fig. S3A-E) . HNF4α/KI67 double staining were performed, revealing that HNF4α + /PH3 + and HNF4α + /KI67 + proliferating hepatocytes were only observed in the PV area ( Fig. 3E and Supporting Fig. S4E ). Furthermore, serial sections showed that most of the KI67 + proliferating cells were located in the PV area, especially the SOX9 + cell area, with very few KI67 + hepatocytes in the CV area (Supporting Fig. S4F ). SOX9/KI67 double staining and quantification of the percentage of KI67 + cells in SOX9 + hepatocytes were performed, and 25% of SOX9 + hepatocytes in the PV area were also KI67 + ( Fig. 3F and Supporting Fig. S4G ). Because the location and SOX9 + expression pattern of these cells resembled those of HybHPs reported, (13) SOX9 and HNF4α double staining was performed on livers from PCN-treated mice to clarify whether these SOX9 + hepatocyte-like cells were HybHPs. SOX9 + hepatocytes located in the PV area were also HNF4α + , suggesting that these SOX9
+ hepatocyte-like cells are HybHPs (Fig. 4A) . Moreover, to verify that SOX9 + hepatocytes in the PV area were HybHPs, SOX9/albumin (ALB) and SOX9/CYP2D6 staining in addition to HNF4α staining were performed. A population of SOX9 + hepatocytes were also positive for hepatocyte markers (Fig. 4B) . To investigate the origin of these HybHPs after PXR activation, an adeno-associated virus (AAV ) Tbg promoter-Cre recombinase vector (AAV-Tbg-Cre), in which Cre recombinase was only expressed in mature hepatocytes, was administered to Rosa26 EYFP reporter mice (Fig. 4C ). AAV-Tbg-Cre injection induced enhanced yellow fluorescent protein (EYFP) expression in more than 99% of hepatocytes, but no other cells in the liver, such as bile duct cells, Kupffer cells, and hepatic stellate cells (HSCs), as reported. (25, 26) No hepatocytes were found without EYFP expression in the PV area after PCN treatment (Fig. 4D) , and some of these cells showed positive SOX9/EYFP staining (Fig. 4E) , suggesting that PCN-induced HybHPs were of hepatocyte origin. Sox9-Cre ERT ;Rosa26 EYFP transgenic mice were then treated with 50 mg/kg of tamoxifen (TAM) to label the preexisting SOX9 + cells, followed by vehicle or PCN administration (Fig. 4F ). Very few hepatocytes were labeled with EYFP in the vehicle group, whereas EYFP + / HNF4α + hepatocyte induction was observed extending along the periportal region in the PCN-treated group (Fig. 4G,H) . These data supported the notion that PXR activation leads to HybHPs induction in the PV area.
pXR aCtiVatioN aCCeleRateD lR
As noted above, PXR activation contributes to regulation of liver size and hepatocyte proliferation in liver, in agreement with earlier studies that absence of PXR suppresses LR. (27) Thus, by which PXR activation regulated LR after two-thirds partial hepatectomy (PHx) was examined (Fig. 5A) . Liverto-body-weight ratios of PCN-treated mice increased progressively and induced augmentative hepatomegaly postsurgery (Fig. 5B,C) . Enlarged hepatocytes in the PCN-treated group were also observed, as revealed by H&E and CTNNB1 histological staining (Fig. 5D ,E and Supporting Fig. S6A) . Furthermore, the number of KI67
+ hepatocytes in the PCN-treated group was higher than in the vehicle-treated group at days 2 and 5 ( Fig. 5F and Supporting Fig. S6B) . Similarly, the number of SOX9 + HybHPs was substantially increased in the PV area of PCN-treated mice ( Fig. 5G and Supporting Fig. S6C ). PXR-accelerated regeneration post-PHx was further confirmed in hPXR mice treated with 50 mg/kg of RIF post-PHx (Supporting Fig. S5A ). RIF also elevated liver-to-body-weight ratio post-PHx (Supporting Figure S5B ,C) and increased cell size (Supporting Figs. S5D,E and S6D). RIFtreated hPXR mice exhibited an increased number of KI67-positive hepatocytes, and their postoperative SOX9 + hepatocytes were significantly increased compared to the vehicle-treated group (Supporting Figs. S5F,G and S6E,F). Interestingly, during LR post-PHx, no induction of SOX9 expression was observed in the vehicle-treated group, but an induction of SOX9 + hepatocytes was found in PCN/RIF-treated PHx mice. During tissue regrowth and LR, there is transient steatosis characterized by accumulation of lipid used as substrates for energy production and membrane synthesis. (28, 29) Pronounced hepatic triglyceride and cholesterol accumulation was observed in PCNtreated mice (Supporting Fig. S6G-J) . Moreover, level of serum ALB was not significantly changed in vehicle-treated mice and RIF/PCN-treated mice postPHx. However, PXR agonists inhibited elevation of serum total bilirubin (TBIL) post-PHx (Supporting Fig. S6K-N) . These data suggested that PXR agonists had the potential to promote LR.
pXR iNDUCeD liVeR eNlaRgeMeNt iN a yapDepeNDeNt MaNNeR
The YAP signaling pathway controls liver size (30) through regulation of hepatocyte size and proliferation as well as induction of ductal/progenitor cells. (31) To determine whether PXR regulates liver growth through the YAP pathway, YAP expression was examined after PCN treatment in WT, Pxr-null, RIF-treated hPXR mice. Yap mRNA levels were measured, and PXR activation induced significant increase in Yap mRNA (Supporting Fig. S7A,B) . YAP is highly expressed in bile duct cells, where PXR agonist treatment induced YAP expression in all mouse lines except Pxr-null mice (Fig. 6A,B) . YAP phosphorylation increases its cytoplasmic retention and inhibits its function as a transcriptional coactivator.
(32) Levels of total YAP and nuclear YAP were significantly increased in PCN-treated WT mice and RIF-treated hPXR mice, whereas cytoplasmic phosphorylated YAP was reduced by both PCN and RIF, indicating that the YAP pathway is activated by PXR agonists (Fig.  6C,D) . In support of this observation, expression of YAP downstream target proteins and proliferation-associated proteins, including the YAP target genes, ankyrin repeat domain 1 (ANKRD1), cysteine-rich angiogenic inducer 61 (CYR61), and connective tissue growth factor (CTGF), and the proliferation-associated proteins, cyclin A1 (CCNA1), cyclin D1 (CCND1), cyclin E1 (CCNE1), and cyclin-dependent kinase 4 (CDK4), were increased in PCN-treated WT mice and RIF-treated hPXR mice, but was not significantly changed in Pxr-null mice (Fig. 6C,D) . However, expression of upstream regulators mammalian Ste20-like kinases 1/2 (MST1/2), p-MST1/2, large tumor suppressor 1/2 (LATS1/2), and phosphorylated LATS1/2 were not significantly changed (Supporting Fig. S7C-F) , suggesting that PXRinduced YAP activation may not be by YAP classical upstream.
PXR and YAP are normally located in the cytoplasm and translocated into the nucleus after activation. (33, 34) To explore the potential interaction of PXR and YAP, co-immunoprecipitation and colocalization analysis were performed. Endogenous PXR selectively bound to YAP in primary hepatocytes (Fig. 6E) , and activation of PXR by RIF enhanced translocation of YAP to the nucleus in HepG2 cells (Fig. 6F) . These data provided evidence that PXR interacts with YAP. Next, AAV Yap short hairpin RNA (shRNA) mice were used to investigate whether PXR-induced liver enlargement depends on activation of the YAP pathway (Fig. 7A) . Hepatic YAP was successfully reduced (Supporting Fig. S8A,B) without interfering PXR activation, as revealed by protein expression of the PXR downstream genes, cytochrome P450, family 3, subfamily a, polypeptide 11 (CYP3A11), UDP glucuronosyltransferase family 1 member A1 (UGT1A1), and glutathione S-transferase mu 2 (GSTM2; Supporting Fig. S8C,D) . Expression of YAP target genes revealed that, by disabling Yap, PCN lost induction of ANKRD1, CYR61, CTGF, CCNA1, CCNE1, and CCND1 ( Fig. 7D and Supporting  Fig. S8E ). Mice exposed to AAV control had a normal liver size, but AAV Yap shRNA-treated mice had a significant decrease in liver mass. PCN treatment induced liver enlargement and an increase in the number of KI67 + and SOX9 + hepatocytes in the presence of YAP, but failed to induce liver enlargement (Fig 7B,C) , hepatocyte size (Fig. 7E,F and Supporting Fig. S8F) , and elevation of the number of KI67 + and SOX9 + hepatocytes in the absence of YAP (Fig7G,H and Supporting Fig. S8G,H) . These results indicated that depletion of YAP prevented PCN-induced liver enlargement and liver cell-fate change. 
Discussion
The liver plays a pivotal role in the metabolism and detoxification of xenobiotics, and hepatic size and mass must be strictly controlled. PXR activation was found to induce liver enlargement (35) and hepatocyte proliferation, (36) but the related molecular signals and mechanisms have not been investigated. The cell types responding to PXR activation also remain unknown. The present study demonstrated that PXR activation induces liver enlargement by increasing hepatocyte size and proliferation. Moreover, PXR activation induces hepatocytes to HybHPs reprogramming. Furthermore, activation of the YAP signaling pathway is necessary for PXR-induced liver enlargement (Fig. 8) . These findings indicate a function of PXR in changing liver size and reprogramming liver cell fate by potentially interacting with the YAP signaling pathway, thus highlighting the mechanism by which PXR activation influences liver size and cell fate. Hepatic response to various stimuli may involve an increase in liver size and functional capacity attributable to an increase in size and/or number of hepatocytes.
Liver size and mass are tightly controlled, and many types of hepatic cells participate in liver-size regulation. Among them, liver stem/progenitor cells play an important role in giving rise to both hepatocytes and cholangiocytes. (37) During persistent and severe liver damage, part of hepatocytes undergo dedifferentiation into liver stem/progenitor cells for LR. (38) HybHPs, a type of progenitor-like cell with lower SOX9 expression compared with cholangiocytes, and LPCs were identified as a preexisting group of periportal hepatocytes with the highest regenerative and proliferative capacity in healthy livers. (13, 39) Few SOX9 + hepatocytes exist under normal conditions, whereas PXR activation promoted an increase of SOX9 + hepatocytes in the PV area, which are also coincident with KI67 + proliferating cells. Of interest, PXR activation can induce KI67 + expression of mature hepatocytes around the PV area. PXR activation reprograms cells to bear double biopotential of HybHP. Enzyme content and subcellular structures of hepatocytes from the periportal (afferent) and perivenous (efferent) zones of the liver parenchyma are varied. Because glycogen synthesis, glycolysis, lipogenesis, ketogenesis, and detoxication are preferentially situated in the CV area, (40) the enlargement of hepatocytes responding to PXR activation was primarily observed around the CV area. On the other hand, PXR-induced, newly formed HybHPs were chiefly located near the PV area, which may attributed to the continuous hepatocyte supply from the SOX9-expressing precursor pool located in the biliary duct. The newborn hepatocytes appeared to migrate very slowly from the PV region to the CV zone.
(5) Thus, PXR activation at the portal-central axis may induce a unique change in hepatic cell diversity that might correspond to different metabolic capacities.
Hepatic enzyme induction is generally an adaptive response associated with an increase in liver weight, induction of gene expression, and morphological changes in hepatocytes. Common xenobiotic enzyme inducers trigger pathways involving the constitutive androstane receptor (CAR), peroxisome proliferator-activated receptor (PPAR), and aryl hydrocarbon receptor. In practice, it was found that these ligandactivated transcription factors can induce hepatocellular hypertrophy. (41, 42) Given that PXR broadly regulates xenobiotic-metabolizing metabolic enzymes, induction of one or more of these enzymes might contribute to PXR-induced hepatic growth. PXR might have a stage-specific effect on metabolic enzyme induction, which provides an energy source to support cell proliferation and tissue overgrowth.
The YAP signaling pathway, a critical regulator of organ and organism size, was shown to regulate hepatocyte proliferation and liver mass. (43) It was also reported that overactivation of YAP leads to dedifferentiation of hepatocytes, which is associated with the appearance of progenitor cells. (31, 44) In the current study, PXR-induced liver enlargement was abolished after YAP suppression using AAV Yap shRNA, indicating that the YAP signaling pathway is essential for PXR-induced liver enlargement. Moreover, PXR regulated expression of YAP downstream genes. As the major downstream effector of the Hippo pathway, unphosphorylated YAP translocates into the nucleus to induce target gene transcription, which is similar to PXR activation. Moreover, PXR is able to recruit members of the p160 family coactivators, such as PPAR gamma coactivator 1α and steroid receptor coactivator 1. (45, 46) Therefore, PXR and YAP might undergo nuclear cotranslocation and coactivation. The present study also demonstrated a proteinprotein interaction between PXR and YAP, which raises the possibility that PXR might regulate YAP activity by coactivator interactions that lead to nuclear translocation. However, the downstream signaling pathway of PXR-YAP in liver hypertrophy remains unclear. PXR is a direct activator of growth arrest and DNA damage-inducible 45 (GADD45 (47) which was reported to be associated with CARinduced liver hypertrophy. (48) Whether GADD45 is involved in PXR-YAP-mediated liver enlargement still requires further study. Moreover, the activation of PXR increased Yap mRNA levels, suggesting the possibility of direct or indirect regulation between PXR and YAP. However, whether PXR could regulate YAP directly or indirectly still needs further study.
PXR was reported to play an important role in LR post-PHx. However, the underlying mechanisms and cell types responding to PXR-related regeneration remain unknown. Post-PHx, all the existing mature cellular populations undergo cell division and proliferation to restore organ weight. A previous study reported that DNA synthesis in hepatocytes and bile duct cells was terminated 4-5 days post-PHx. (49) In the present study, PXR activation rapidly restored liver mass by day 5 post-PHx, yet some hepatocytes remained proliferative and dedifferentiated along the hepatic PV. These findings raise the possibility that both hepatocyte self-duplication and dedifferentiation into progenitor-like cells contribute to PXR-accelerated LR. LR is a vital recovery process after liver damage, and thus promoting regeneration through the activation of PXR might be an important strategy to promote LR associated with liver resection, liver cancer, and acute liver failure. The present study illustrated that many clinical drugs, such as nifedipine, mifepristone, and corticosterone, activate PXR and induce liver enlargement. LR is the result of hepatocyte hyperplasia and hypertrophy, (50) which could be modulated by PXR activation. Thus, the effect of these drugs to induce liver enlargement and promote LR should be considered before their potential clinical use.
PXR activation has broad biological and physiological implications. Thus, it is vital to fully understand the biological and physiological properties and functions of PXR. Overall, this study demonstrated that PXR activation induces liver enlargement and promotes LR by increasing cell size, inducing hepatocytes to HybHP reprogramming, and promoting hepatocytes and HybHP proliferation. However, the relative contributions of these three mechanisms to liver enlargement remain unclear, and further studies are needed to clarify their relationship. Moreover, interaction with the YAP-signaling pathway is a key mechanism in PXR-induced liver enlargement and accelerated regeneration. These findings provide a clinically relevant argument for using PXR as a potential therapeutic target for promoting hepatic development and liver repair.
